BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32415497)

  • 1. TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
    Zhang LY; Zhang YQ; Zeng YZ; Zhu JL; Chen H; Wei XL; Liu LJ
    Breast Cancer Res Treat; 2020 Jul; 182(1):21-33. PubMed ID: 32415497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-193 promotes cell proliferation and invasion by ING5/PI3K/AKT pathway of triple-negative breast cancer.
    Xu JH; Zhao JX; Jiang MY; Yang LP; Sun ML; Wang HW
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3122-3129. PubMed ID: 32271430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis.
    Jin X; Zhu L; Cui Z; Tang J; Xie M; Ren G
    Clin Transl Oncol; 2019 Sep; 21(9):1207-1219. PubMed ID: 30767161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
    Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G
    Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPR56 promotes proliferation of colorectal cancer cells and enhances metastasis via epithelial‑mesenchymal transition through PI3K/AKT signaling activation.
    Ji B; Feng Y; Sun Y; Ji D; Qian W; Zhang Z; Wang Q; Zhang Y; Zhang C; Sun Y
    Oncol Rep; 2018 Oct; 40(4):1885-1896. PubMed ID: 30066935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.
    Yang Q; Ji G; Li J
    Cancer Biol Ther; 2020; 21(3):278-291. PubMed ID: 31696760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
    Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
    Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
    Colín-Val Z; López-Díazguerrero NE; López-Marure R
    J Steroid Biochem Mol Biol; 2021 Apr; 208():105818. PubMed ID: 33508440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
    Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
    Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
    Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
    Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
    Xu JH; Wang Y; Xu D
    Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer Invasion and Metastasis by mPRα Through the PI3K/Akt Signaling Pathway.
    Wu X; Sun L; Wang X; Su P; Li Z; Zhang C; Wang Y; Gao P; Ma R
    Pathol Oncol Res; 2016 Jul; 22(3):471-6. PubMed ID: 26608797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
    Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
    Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.